Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · 4A
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
Deficit reduction issues; Part D; Rebates
Source: Senate LDA
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Intellectual property; HR 3497
Intellectual property issues; HR 3497
Intellectual property; HR 3497
Medicare Decisions Accountability Act of 2011
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare Part D Non-Interference, Rebate Issues, Medicare Decisions Accountability Act of 2011 - IPAB Repeal (HR 452)
Medicare Decisions Accountability Act of 2011
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare Part-D non-interference and rebate issues; Medicare Decisions Accountability Act of 2011 (IPAB repeal) (HR 452);
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Carbon Capture and Sequestration Deployment Revenue Act of 2010
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
AMP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872 & HR 3590)
Carbon Capture and Sequestration Deployment Revenue Act of 2010
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
AP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872, HR 3590)
Patient Reform Act (S 515); Counterfeit medicines
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
Patient Reform Act (S 515); Counterfeit medicines
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
AMP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872 & HR 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
AP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872, HR 3590)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Finanical derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
AMP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872 & HR 3590)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
AP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872, HR 3590)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Waxman Medicare part-D Non-Interference; Comparative Effectiveness Research (HR 2502, HR 2824); Medicare Commission
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
Doctor-Patient Relationship and Research Protection Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
Doctor-Patient Relationship and Research Protection Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Waxman Medicare part-D Non-Interference; Comparative Effectiveness Research (HR 2502, HR 2824); Medicare Commission
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patient-Centered Outcomes Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Patient-Centered Outcomes Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
America's Healthy Future Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Physician Payments Sunshine Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Physician Pathology Services Continuity Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Wall Street Reform and Consumer Protection (HR 4173)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Transparency (HR 1669)
Transparency (HR 1669)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Patent protection; Drug shortages; 340B issues; PPACA; FDA modernization, 21st Century Cures
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · Q4
Deficit reduction issues; Part D; Rebates
Patent protection; Drug shortages; 340B issues; PPACA; FDA modernization, 21st Century Cures
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · third_quarter · Q3
Deficit reduction issues; Part D; Rebates
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Tax reform
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Colombia biologics
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · second_quarter · Q2
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · first_quarter · Q1
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Tax reform
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · fourth_quarter · Q4
Deficit reduction issues; Part D; Rebates
Tax retorm
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · third_quarter · Q3
Tax retorm
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Intellectual property; HR 3497
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Intellectual property; HR 3497
Tax retorm
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Tax reform
Intellectual property; HR 3497
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Intellectual property; HR 3497
Tax reform
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · first_quarter · Q1
Intellectual property; HR 3497
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · fourth_quarter · Q4
Intellectual property; HR 3497
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · third_quarter · Q3
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Intellectual property; HR 3497
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · second_quarter · Q2
PDUFA reauthorization; Patent protection
Intellectual property issues; HR 3497
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · first_quarter · Q1
Intellectual Property Issues
PDUFA reauthorization, Patent Protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · fourth_quarter · Q4
Patent Reform
Debt Commission; Patent Protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · third_quarter · Q3
Patent reform; Anti-counterfeiting; Patient Safety
Bipartisian Tax Fairness and Simplification Act (S727)
Patent Protection, PDUFA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · second_quarter · Q2
Medicare Part-D non-interference and rebate issues; Medicare Decisions Accountability Act of 2011 (IPAB repeal) (HR 452);
PFUFA V; Patient Protection and Affordable Care Act;
Bipartisian Tax Fairness and Simplification Act (S727)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · first_quarter · Q1
340 B Legislation, PDUFA V, Importation, Patient Protection and Affordable Care Act
Medicare Part D Non-Interference, Rebate Issues, Medicare Decisions Accountability Act of 2011 - IPAB Repeal (HR 452)
Corporate Tax Reform, Patent Reform (S 23, HR 1249)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · fourth_quarter · Q4
Financial derivatives (HR 4173)
Patient Reform Act (S 515); Counterfeit medicines
Financial derivatives (HR 4173)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · third_quarter · Q3
Patient Reform Act (S 515); Counterfeit medicines
Dream Act
Financial derivatives (HR 4173)
Financial derivatives (HR 4173)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · second_quarter · Q2
Financial derivatives (HR 4173)
Financial derivatives (HR 4173)
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · first_quarter · Q1
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · fourth_quarter · Q4
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Wall Street Reform and Consumer Protection (HR 4173)
Waxman Medicare part-D Non-Interference; Comparative Effectiveness Research (HR 2502, HR 2824); Medicare Commission
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · third_quarter · Q3
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · second_quarter · Q2
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · 2A
Sunshine Act (S 2029, HR 5605)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · 1A
Transparency (HR 1669)
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · fourth_quarter · Q4
Medicare, Medicaid
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · third_quarter · Q3
Waxman Medicare Part D non-interference,
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · Q1
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · year_end · YY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · mid_year · MM
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Medicare (S 250 & HR 4), SCHIP
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · year_end · YY
Health Care Reform Pricing Issues Importation
Intellectual Property Patent Reform (S3818)
International Trade Issues -- Peru FTA, Poland Price Cut, Germany Jumbo Groups, Japan Pricing & Regulatory Reform, Korea FTA, Russia WTO
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2005 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2005 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2004 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2003 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2002 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2000 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
1999 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Medicare Part D non-interference and rebate issues
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
America Invents Act (patent reform)(HR 1249); Anti-Counterfeiting; Patient safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
The America Invents Act of 2011 (HR 1249), BiPartisan Tax Fairness and Simplifiation Act (S 727)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Dream Act
AP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872, HR 3590)
Finanical derivatives (HR 4173)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Financial derivatives (HR 4173)
AMP Pricing (S 3590, HR 4872); Healthcare Reform (HR 4872 & HR 3590)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Financial derivatives (HR 4173)
Healthcare Reform (HR 4872 & HR 3590)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sunshine Act (S 2029, HR 5605)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sunshine Act (S 2029, HR 5605)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Transparency (HR 1669)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Follow-on Biologics (HR 1956)
Direct to Consumer Advertising
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Follow-on Biologics (S 1695)
Prescription Drug User Fee Act (S 1082 & HR 2900)
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Health Technology
Medicare implementation Non-interference MMA & Patient Assistance Programs Mental Health Access
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)